Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

  • End date
    Aug 24, 2023
  • participants needed
  • sponsor
    ACADIA Pharmaceuticals Inc.
Updated on 24 September 2021


The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.

Condition Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Treatment Pimavanserin
Clinical Study IdentifierNCT03623321
SponsorACADIA Pharmaceuticals Inc.
Last Modified on24 September 2021


Yes No Not Sure

Inclusion Criteria

Subject satisfied all entry criteria for the antecedent pimavanserin study
Subject completed the antecedent study; or was participating in a pimavanserin study that the Sponsor ended early
Has a designated study partner/caregiver who meets the following requirements
In the Investigator's opinion, is in contact with the subject frequently enough to accurately report on the subject's symptoms and whether or not the subject is taking the study drug
In the Investigator's opinion, is considered reliable in providing support to the subject to help ensure compliance with study treatment, study visits, and protocol procedures
Is fluent in the local language in which study assessments will be administered
Agrees to participate in study assessments, has the capacity to provide informed consent, and provides written consent to participate in the study
Subject is willing and able to provide informed consent
If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception or be abstinent during the study and 1 month following completion of the study

Exclusion Criteria

Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study, due to AEs, medical condition, or noncompliance with investigational product or study procedures in the antecedent study, or is judged to be a danger to self or others
Is in hospice, is receiving end-of-life palliative care, or has become bedridden
Has any of the following ECG results at the EOT/ET visit of the antecedent study
If the subject is not on citalopram, escitalopram, or venlafaxine
QTcF >450 ms, if QRS duration <120 ms
ii. QTcF >470 ms, if QRS duration 120 ms
b. If the subject is on citalopram, escitalopram, or venlafaxine
i. QTcF >425 ms, if QRS duration <120 ms
ii. QTcF >450 ms, if QRS duration 120 ms
\. Has a heart rate <50 beats per minute. If bradycardia is secondary to
iatrogenic or treatable causes and these causes are treated, a heart rate
assessment can be repeated at the EOT/ET visit of the antecedent study
\. Has clinically significant laboratory abnormalities in the antecedent
study that, in the judgment of the Investigator or Medical Monitor, would
jeopardize the safe participation of the subject in the study; OR
would interfere with the conduct or interpretation of safety or efficacy evaluations in the study
Is suicidal at Visit 1 (Baseline)
Has developed a medical condition that in the judgment of the Investigator, would increase the risk associated with taking study medication or significantly interfere with the conduct or interpretation of the study
Requires treatment with a medication or other substance that is prohibited by the protocol
Has a significant sensitivity or allergic reaction to pimavanserin or its excipients
Is an employee of ACADIA, or has a family member who is an employee of ACADIA
Additional inclusion/exclusion criteria apply. Patients will be evaluated at
screening to ensure that all criteria for study participation are met
Patients may be excluded from the study based on these assessments (and
specifically, if it is determined that their baseline health and psychiatric
condition do not meet all pre-specified entry criteria)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note